Justin Marciano
justinmarciano2018@gmail.com
+1 201 312 7783

Arvinas, Inc.

Postmortem on a PROTAC Pioneer: The Vepdegestrant Phase III Failure

Key takeaways: Hold Rating with $8.00 Price Target: Vepdegestrant (ARV-471), Arvinas's (NASDAQ: ARVN) lead PROTAC degrader and once promising asset in ER+/HER2- breast cancer, failed its pivotal Phase III VERITAC-2 trial. This outcome was the unavoidable result of a disconnect between the drug's scientific hypothesis and its molecular properties. My analysis concludes the failure of VERITAC-2 was due to poor medicinal chemistry and pharmacokinetics, which were insufficient in translating biological activity into a clinically meaningful benefit.

The original investment thesis had been built on a compelling scientific basis and "encouraging" Phase II VERITAC single-arm study data. My forensic analysis of this single-arm study reveals the 38% Clinical Benefit Rate (CBR) was concealing an Objective Response Rate (ORR) of just 4.5%. This flat efficacy signal failed to de-risk the program and foreshadowed the subsequent pivotal trial failure.

This report presents a rigorous postmortem analysis, examining the compromised preclinical/Phase II data and the Phase III failure that ultimately sealed its fate. My DCF-based valuation yields a floor valuation of ~**$7.80 per share**, and I believe the market is now appropriately pricing ARVN as a specialty commercial asset-backed company. I rate it a **HOLD**. My analysis includes:

- The molecular defects and scientific rationale underlying the Vepdegestrant program.
- The early-stage clinical data were unpredictable but drove the company's valuation.
- The pivotal Phase III data confirmed the drug's status as a niche product, not a blockbuster.

Finally, this report concludes that this was mostly a molecule-specific failure that is a valuable cautionary tale for the PROTAC space. The objective is to provide a complete, scientific, and financial postmortem of the failure and to estimate the residual value of the company.

Table of Contents

Background:

Company Overview: Company Overview: Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biopharmaceutical company leading the way in the development of a new class of therapeutics based on targeted protein degradation. Arvinas was founded by Dr. Craig Crews, whose previous research at Proteolix enabled the development of the blockbuster multiple myeloma drug Kyprolis (Crews, Yale School of Medicine). With this strong scientific validity, the company's proprietary platform is centered on Proteolysis Targeting Chimeras (PROTACs), bifunctional small molecules that target disease-causing proteins by hijacking the body's own ubiquitin-proteasome system to selectively degrade them. Vepdegestrant (ARV-471) was the company's lead clinical drug and the lead candidate in this new platform.

The Disease & Target (ER+/HER2- Breast Cancer): Estrogen receptor-positive (ER+) breast cancer occurs in roughly 70% of all cases. In the last decade, the therapeutic backbone has been the blockade or modulation of the Estrogen Receptor (ER) to avoid tumor progression (Harbeck, 2016). Notwithstanding that, resistance to these therapies remains a serious clinical issue, typically mediated by the generation of mutations within the ER gene (ESR1) that allow ligand-independent, constitutive ER activation of the tumor (Fribbens et al., 2016). This creates a significant and urgent unmet need for next-generation therapies that are able to effectively eliminate the ER protein, regardless of mutational status.

The Vepdegestrant Opportunity: Vepdegestrant was designed as a best-in-class ER degrader with potential to initiate a revolutionary treatment paradigm for ER+/HER2- breast cancer. The investment thesis was built on a clear, evidence-based narrative that began several years ago, before dosing the first patient.

Compared to other Selective Estrogen Receptor Degraders (SERDs) like elacestrant and fulvestrant, which are potentially encumbered by inadequate degradation or problematic pharmacokinetics, vepdegestrant's new PROTAC strategy held out hope for a more effective and efficient solution. Preclinical data were strong; as early as 2018, the company reported that combining ARV-471 with palbociclib, a CDK4/6 inhibitor, caused superior tumor growth inhibition versus the combination of fulvestrant and a CDK4/6 inhibitor, immediately establishing a "best-in-class" story (Snyder et al., 2021).

This first promise was followed by its capacity for fighting recognized resistance mechanisms. Vepdegestrant was shown preclinically to suppress the growth of tamoxifen-resistant, ESR1 mutant tumors while significantly reducing ER protein levels. Having a favorable profile for once-daily oral administration, vepdegestrant emerged as a potential blockbuster therapy and, perhaps even more importantly, a resounding validation of Arvinas's broader PROTAC platform.

Preclinical Deep-Dive: The Disconnect Between an Elegant Theory and a Flawed Molecule

The entire Vepdegestrant investment thesis was based on a strong preclinical story that combined an established biological target with a novel and potent mechanism of action (MOA). The scientific rationale was robust, and the early data were extremely strong. However, a deeper analysis reveals that this elegant theory was embodied by a fundamentally flawed molecule, creating a significant and ultimately terminal disconnect between the preclinical promise and the clinical result. To understand the failure, one must first critically analyze the scientific foundation that fueled the optimism.

Part 1) The Molecular Rationale: A Valid Target, A Critical Dependency

A Clinically Established and High-Priority Target (ERα): The molecular basis for resistance is well documented. While ESR1 mutations are rare in primary tumors (<4%), they become a hallmark of acquired resistance following endocrine therapy, with frequencies rising to 40% in the metastatic setting (TCGA Network, 2012; Fribbens et al., 2016). These mutations induce a conformational change in the receptor's Ligand-Binding Domain (LBD), locking it into a constitutively active state independent of estrogen signaling (Jeselsohn et al., 2015). This creates a therapeutic problem that simple inhibition cannot solve and necessitates a paradigm shift towards the complete elimination of the ERα protein. This was the elegant, central hypothesis that underpinned the Vepdegestrant clinical program.

A Critical Dependency: The E3 Ligase: Even though ERα was the intended target, the PROTAC mechanism introduces a critical, generally-overlooked dependency: the E3 ligase. Vepdegestrant is inert without its essential partner, the Cereblon (CRBN) E3 ligase, which it uses to tag ERα for destruction (Snyder et al., 2021). This means the drug's success is entirely dependent on the assumption that CRBN is reliably and highly expressed within the tumor cells of every patient. Variability or down-regulation of CRBN expression in tumor tissue represents a potential mechanism for intrinsic drug resistance, a risk factor completely independent of the ERα target itself, and one that is not typically measured in breast cancer patients (Chamberlain et al., 2019).[1]

Part 2) The Pharmacological Design: An Innovative but Complex Modality

The PROTAC Mechanism: Hijacking the Cell's Machinery: Arvinas's Vepdegestrant (ARV-471) was designed to be a highly selective solution. As a Proteolysis Targeting Chimera (PROTAC), it represented a fundamentally different chemical modality. Instead of simply blocking the receptor, a PROTAC acts as a matchmaker, using a bifunctional molecule to link the

---

[1] *Analyst Note: Publicly available data from sources like The Cancer Genome Atlas (TCGA) show that CRBN mRNA expression can be variable across breast cancer patient samples, suggesting that a subset of patients may have intrinsically low levels of this essential E3 ligase, predisposing them to treatment failure.*

target protein (ERα) to an E3 ligase, effectively hijacking the cell's own garbage disposal system (the proteasome) to tag and destroy the protein.


Figure 1: Schematic of the PROTAC Mechanism of Action:
General mechanism for a PROTAC degrader using Arvinas's ARV-771 (a BRD4 degrader) as an example. The PROTAC molecule (center) acts as a bridge, bringing the target protein (left) into proximity with an E3 ligase (purple). This proximity allows the E3 ligase to attach a poly-ubiquitin chain to the target, marking it for destruction by the proteasome. Vepdegestrant uses the same core mechanism to degrade the ER (Raina et al., 2016).

This mechanism provides a compelling theoretical therapeutic case built on two key advantages:
- Event-Driven Catalysis: Because one PROTAC molecule can trigger the degradation of multiple target proteins, it has the potential for more potent and complete target removal than a traditional 1-to-1 inhibitor.
- Overcoming Resistance: By targeting the receptor protein for destruction, PROTACs were hypothesized to be effective even against mutated forms of ERα that might be resistant to traditional inhibitors.

Beyond the Diagram: The Centrality of the Ternary Complex: This elegant mechanism is governed by complex biophysics, most critically the formation of what is known as the ternary complex; the physical "handshake" between ERα, Vepdegestrant, and Cereblon. The stability, cooperativity, and specific 3D orientation of this complex are what determine the speed and efficiency of degradation. Poor ternary complex formation is a common failure mode for the PROTAC platform, and while preclinical data showed degradation occurred, it provided no direct evidence of the efficiency of this complex formation, representing a key translational risk.

An Inherent Platform Liability: The "Hook Effect": Furthermore, the bifunctional nature of PROTACs creates a known pharmacological liability: The "Hook Effect." At extremely high concentrations, the drug can become less effective as the PROTAC molecules saturate ERα and Cereblon separately, forming non-productive binary pairs and stopping the formation of the active ternary complex. This phenomenon creates a small therapeutic window, making clinical dose exploration exceptionally difficult and risking efficacy failures if drug concentrations are not precisely controlled.

Part 3) The Preclinical Evidence: Building the "Best-in-Class" Narrative

A scientific hypothesis is only a starting point; for a drug to be seriously considered, that hypothesis must be proven with a series of substantial data. Arvinas systematically built the case for Vepdegestrant by answering two fundamental questions in their preclinical work: First, is the molecule highly selective and precise? And second, does it work in models of the most malignant forms of cancer?

Demonstrating On-Target Selectivity and Molecular Precision: A major concern for any PROTAC is the potential for unintended collateral damage. By hijacking the cell's own machinery, is there a risk of destroying other essential proteins by mistake? The preclinical evidence provided a clear answer. Employing advanced proteomics, measuring the level of thousands of proteins within a cell simultaneously, researchers showed that Vepdegestrant was exceptionally precise (Fig. 2).


Figure 2: *Vepdegestrant is highly selective for the Estrogen Receptor*
(TMT proteomic profile of MCF7 cells following a 7-hour incubation with 100 nmol/L vepdegestrant. The ER (encoded by ESR1) protein is the most statistically and quantitatively significantly decreased protein. Close to threshold cutoffs, although still significant, is the PGR. (Gough et al., 2024)

This result was a crucial de-risking event. It provided strong evidence that Vepdegestrant's activity was highly selective for its intended target under controlled, preclinical conditions. Notably, the progesterone receptor (PGR), a key hormone receptor, was also significantly degraded. This highlights a key PROTAC design challenge: distinguishing undesirable off-targets from potentially desirable polypharmacology.

Proving Preclinical Efficacy; Inducing Tumor Regression in Resistant Models: With selectivity established, the next challenge was to prove the drug worked in cases that mirror human clinical resistance. Preclinical testing utilized mouse models of aggressive tumors.

Figure 3: *Vepdegestrant Degrades ER & Induces Tumor Regression in Resistant Models*
(A) In a living tumor model, vepdegestrant achieved ≥90% degradation of the ER protein, confirming potent activity. (D) In a patient-derived tumor model with a key ESR1 resistance mutation (Y537S), the drug induced significant tumor regressions and outperformed the standard-of-care, fulvestrant. (E) Critically, even in a model where the cancer had already become resistant to CDK4/6 inhibitors, the most common clinical scenario, vepdegestrant still demonstrated powerful anti-tumor activity. (Gough et al., 2024)

This was the preclinical proof-of-concept (Fig. 2 & 3). The findings showed that ARV-471 was highly selective, induced potent proteolysis in living systems, and induced tumor regressions in challenging, resistant environments. With the mechanism now established in these preclinical models, the issue was whether Vepdegestrant could overcome the intrinsic chemical challenges of the PROTAC platform itself.

Part 4) The Physicochemical Reality: A Fundamentally Flawed Molecule

Despite the compelling biological and pharmacological data, the investment thesis rested on the hope that Vepdegestrant could overcome its own challenging molecular properties.

The "Druggability" Problem and the PROTAC Model: The PROTAC model is not without its own inherent scientific and chemical risks. PROTACs are big, bulky, complex molecules that operate in a three-part system (target-binder, linker, E3-binder), creating significant challenges.

- The Selectivity & Affinity Challenge: One of the primary challenges is maintaining preclinical selectivity in human clinical trials. Bifunctionality of the molecule threatens "off-target" degradation, leading to unforeseen toxicity. Moreover, a high affinity for both the target and the E3 ligase simultaneously is a difficult feat.
- The Physicochemical Challenge: The large size and complex structure of PROTACs often lead to poor "drug-like" properties, such as low oral bioavailability and metabolic instability. Overcoming these pharmacokinetic challenges was Arvinas' biggest clinical trial risk.

Table 1: Comparative Molecular Properties

Property	Vepdegestrant (PROTAC)	Elacestrant (SERD)
Molecular Weight	723 Da	458 Da
LogP	6.4	6.3
Rotating Bonds	7	10
Heavy Atom #	54	34
Complexity Score	1310	578

Table 1: *This table quantifies the significant "druggability" challenge inherent in Vepdegestrant's PROTAC design. While both molecules are highly lipophilic (LogP > 6), Vepdegestrant's molecular properties present several clear red flags when analyzed through the lens of established medicinal chemistry principles for oral bioavailability. (Source: PubChem or other chemical databases.)*

- **Violation of "Lipinski's Rule of 5":** While both molecules are highly lipophilic (LogP > 6), foundational research suggests that molecular weight is often a surrogate for other negative properties. Vepdegestrant's MW of 723 Da is a major outlier, nearly 60% larger than Elacestrant and drastically exceeding the informal <500 Da guideline, which often correlates with poor membrane permeation and higher clearance rates. The size and high lipophilicity represent a fundamental absorption and trafficking challenge.
- **Excessive Molecular Complexity:** The complexity score of 1310 for Vepdegestrant is more than double that of Elacestrant. This suggests a more intricate structure that can present multiple, unpredictable surfaces for interaction with metabolic enzymes and off-target proteins, increasing the risk of both poor pharmacokinetics and unpredictable toxicity.

The Fragile Hope: A Gamble on PK/PD Uncoupling

The challenging physicochemical properties of Vepdegestrant meant that its success hinged entirely on a pharmacological principle that PROTAC degraders uniquely rely on: PK/PD uncoupling (i.e., "hit and run"). The assumption was that even transient drug exposure (Pharmacokinetics, PK) might produce a durable, long-lasting biological effect (Pharmacodynamics, PD), since the target protein takes a long time to be resynthesized.

The preclinical findings, from Gough et al. 2024, demonstrated this dynamic perfectly in mouse models: an unstated (and therefore likely short) PK profile was shown to produce a profound and durable PD effect, leading to tumor regressions. The entire program was therefore a high-stakes wager on whether this fragile relationship could be replicated in human patients.

Early Clinical Data Confirms the Gamble and Reveals Its Flaw: The first in-human clinical data provide the missing numbers and confirm the precarious nature of this bet. A Phase 1 study in Japanese patients (NCT05463952) established that Vepdegestrant has a clinically effective half-life of approximately 20.2 hours (Table 2). This means the drug is largely cleared from a patient's system within about four days (Iwata et al., 2025).

Table 2: Vepdegestrant (n=6) Clinical Pharmacokinetic Parameters (Multiple Doses)

Analyte	Vepdegestrant		ARV-473[a]	
Parameters (unit)	Single dose	Multiple doses	Single dose	Multiple doses
C_{max} (ng/mL)	630.9 (57)	1056 (54)	74.08 (61)	292.5 (69)
C_{trough} (ng/mL)	NA	496.3 (57)	NA	238.1 (69)
T_{max} (hr)	4.74 (3.75–6.28)	4.69 (3.72–6.03)	23.5 (23.0–24.1)	6.83 (3.83–12.0)
$t_{1/2eff}$ (hr)	NA	20.23 ± 6.70	NA	71.60 ± 10.84
AUC_{24} (ng•hr/mL)	10,400 (58)	18,310 (57)	1289 (61)	6175 (70)
R_{ac}	NA	1.760 (21)	NA	4.790 (13)

Table 2: All *data shown are geometric mean unless otherwise noted, except T_{max}, which is shown as median (range), and $t_{1/2eff}$, which is shown as arithmetic mean ± standard deviation. ARV-473 is an epimer of vepdegestrant (Iwata et al., 2025).*

Critically, this study also proved that the drug was biologically active at this dose. Pharmacodynamic biomarker analysis showed that Vepdegestrant successfully engaged its target, leading to a profound reduction in ESR1 mutant VAF in patient ctDNA (Fig. 4). This confirms the PROTAC mechanism was working in humans exactly as it did in mice.

Figure 4: *Change in ESR1 variant allele fraction in individual patients. Plots show the change in ESR1 VAF in 2 patients. Patient 1 was on treatment as of the cutoff date; thus, no EOT sample was available. C cycle, D day, EOT end of treatment, ESR1 estrogen receptor 1 gene, VAF variant allele fraction (Iwata et al., 2025).*

This leads to a clear and fatal disconnect: the drug was biologically active, yet clinically ineffective. The Phase 1 trial (NCT05463952), in just six patients, reported a 0% Objective Response Rate (ORR), with the majority of the cohort (67%) experiencing progressive disease (Iwata et al., 2025).

While the small sample size of an early safety study must be considered, the nature of this initial clinical signal was profoundly negative, particularly when weighed against the drug's "best-in-class" preclinical promise of deep tumor regressions. For a drug with a well-validated target, the complete absence of any tumor shrinkage provided the first compelling clinical evidence that the foundational PK/PD uncoupling hypothesis was failing. The approximate 20-hour half-life was sufficient to engage the target and produce a biomarker effect, but it was insufficient to produce a meaningful anti-tumor effect. This weak clinical signal was the first indication that the elegant preclinical theory, embodied by a flawed molecule, could not survive the reality of human pharmacokinetics.

Clinical Trial Postmortem: The Disconnect

Clinical Research:

Overview: The ultimate failure of Vepdegestrant can be traced through its clinical development program, where the fundamental risks identified in the preclinical analysis systematically materialized. The disconnect between a compelling biological theory and a flawed molecule became increasingly apparent as the program advanced from early-stage, open-label studies to the unforgiving rigor of a pivotal, randomized trial. The clinical development strategy was anchored by three key studies, each with a distinct and critical role in the investment thesis.

- The Phase I/II VERITAC Study (NCT04072952): This first-in-human study served a dual purpose. Its initial dose escalation phase was designed to establish the drug's safety and pharmacokinetic profile, while the Phase II expansion cohort was intended to provide the first signal of clinical efficacy. It was the data from this study that fueled initial investments and drove the company's valuation, making its design and limitations a central focus of this postmortem.

- The Phase III VERITAC-2 Study (NCT05654623): This was the definitive pivotal trial and the first of two major "shots on goal." As a randomized, controlled study, it was designed to definitively prove Vepdegestrant's superiority as a monotherapy over the established standard-of-care (SOC), fulvestrant. The outcome of this trial was the primary catalyst for the program's collapse.

- The Phase III VERITAC-3 Study (NCT05909397): This cancelled trial was designed to evaluate Vepdegestrant in combination with the CDK4/6 inhibitor palbociclib. Its objective was to confirm the synergistic anti-tumor effects observed in preclinical models and to support a potential first-line indication. The viability of this combination study was dependent on the monotherapy results from VERITAC-2.

---

[2] **Analyst Note:** The Vepdegestrant clinical program includes numerous studies. For the purpose of this postmortem, my analysis will focus exclusively on the registration-enabling trials that formed the core of the investment thesis: the foundational Phase I/II VERITAC study and the pivotal Phase III VERITAC-2 and VERITAC-3 trials. Data from other supporting studies, such as the early-stage TactiveU program or the Japanese Phase 1 study, will be referenced where relevant to provide critical context for this pivotal program.

Phase I/II "VERITAC" Study - NCT04072952

Following the initial dose escalation phase that established the drug's ~20-hour half-life and provided the first proof of biological activity in humans, the investment thesis for Vepdedegestrant was fully formed by the results of the Phase II VERITAC expansion cohort (NCT04072952). This single-arm study, in 71 (n=71) heavily pretreated patients, was designed to provide the key efficacy and safety data needed to justify advancing into a costly pivotal program. The results, presented in late 2022, were positioned as a major success and became the primary driver of the company's multi-billion-dollar valuation (Arvinas, 2022).

Part A: "Best-in-Class" Profile in a Difficult-to-Treat Population

The VERITAC data fueled significant optimism by successfully demonstrating three critical points that supported a "best-in-class" narrative.

1. **On-Target Proof of Mechanism in Humans:** The trial provided the first definitive human proof-of-concept for the PROTAC platform's superiority in this indication. Paired tumor biopsies from patients treated with Vepdegestrant showed a median ER degradation of 69%, with a mean degradation of 71%. This confirmed that the novel mechanism was working as intended and was substantially more potent than the 40-50% degradation typically seen with the existing SERD, fulvestrant (Gough et al., 2024).

Figure 5: *ER Degradation in Paired Tumor Biopsies from Veritac Patients. An Aqua score represents an Automated Quantitative Analysis (AQUA) system that measures a biomarker's intensity from a tissue sample.*

2. **Promising Efficacy Signals in a Heavily Pre-Treated Population:** The study showed encouraging clinical activity in what was arguably the most treatment-resistant patient population ever studied for a novel endocrine agent. Of the 71 patients, 100% had received a prior CDK4/6 inhibitor, 79% had received prior fulvestrant, and 73% had received prior chemotherapy. In this setting, Vepdegestrant achieved a Clinical Benefit Rate (CBR) of 38.0%. The signal was even stronger in the key subgroup of patients with ESR1-mutant tumors, where the CBR reached 51.2%, suggesting a durable benefit in a population with high unmet need.

Table 3: Clinical Benefit Rate (CBR) in the Veritac Phase II Expansion Cohort

Primary Endpoint: Clinical Benefit Rate[a] (VERITAC)

	200 mg QD (n=35)	500 mg QD (n=36)	Total (N=71)
CBR, % (95% CI)	37.1 (21.5–55.1)	38.9 (23.1–56.5)	38.0 (26.8–50.3)
Patients with mutant *ESR1*	(n=19)	(n=22)	(n=41)
CBR, % (95% CI)	47.4 (24.4–71.1)	54.5 (32.2–75.6)	51.2 (35.1–67.1)

- CBR consistent with Phase 1 dose escalation data
  - Phase 1: 40% in all patients, 50% in patients with *ESR1*-mutant tumors
- Patients with WT ESR1 (n=25) exhibited CBR rate of 20%

[a]Rate of confirmed complete response or partial response or stable disease ≥24 weeks
CBR=clinical benefit rate; *ESR1*=estrogen receptor 1 gene; QD=once daily

Table 3: *Clinical Benefit Rate (CBR) in the Veritac Phase II Expansion Cohort (n=71). While Patients with mutant ESR1 were demonstrated to perform more favorably, it is important to note the wide confidence intervals within σ (stdev) (Source: Hamilton, P. et al., 2022).[3]*

3. **A Favorable and Differentiated Safety Profile:** The tolerability of Vepdegestrant was positioned as a key advantage. At the recommended Phase 3 dose of 200 mg once daily, there were zero dose reductions and only one discontinuation due to a treatment-emergent adverse event. The most common side effects were mild (Grade 1/2) fatigue and nausea. This clean safety profile suggested the drug would be well-suited for long-term use and, critically, for combination with other cancer therapies.

Taken together, these results created a powerful narrative: a drug with a superior mechanism, promising efficacy in a resistant population, and a clean safety profile was ready for Phase 3.

---

[3] **Analyst Note:** The significant performance gap between the ESR1-mutant cohort (51.2% CBR) and the wild-type cohort (20% CBR) is a critical finding that re-frames the drug's market potential. Acquired ESR1 mutations are present in approximately 25-40% of metastatic patients who have progressed on prior endocrine therapy (Fribbens et al., 2016). While the 51.2% CBR in this group was compelling, the far weaker 20% CBR in the wild-type majority strongly suggested Vepdegestrant's true potential was as a highly effective but niche therapy for this specific patient subset, not the blockbuster priced into the stock.

Part B: A Critical Analysis - The Flaws Beneath the Surface

Despite the compelling narrative, a deeper analysis of the VERITAC data reveals significant weaknesses that foreshadowed the eventual Phase III failure.

1. **The Peril of a Single-Arm Study:** The most critical limitation is the study's design. As a single-arm, open-label trial, VERITAC lacks a randomized control arm. This makes it impossible to attribute the observed 3.7-month median Progression Free Survival (mPFS) to the drug versus confounding factors like patient selection bias or the natural, variable course of the disease in a small cohort.

2. **The Efficacy Signal Was Weaker Than It Appeared:** While the 38% CBR was the headline number, the underlying data was far less impressive.
   - An Extremely Low Objective Response Rate (ORR): The waterfall plot from the study reveals that the vast majority of patients experienced stable disease, not tumor shrinkage. In the 44 patients with measurable disease, only two had a confirmed partial response, yielding a true ORR of just 4.5%. This profound lack of tumor regression is a major red flag for a drug with "best-in-class" aspirations.
   - A Miss on the Preclinical PD Promise: The median human ER degradation of 69%, while notable, falls significantly short of the ≥90% degradation consistently achieved in preclinical models that led to deep tumor regressions. This suggests a potential gap in translational potency, likely due to the drug's challenging pharmacokinetic profile.

Tumor Response[a] (VERITAC)

[a]Includes patients with measurable disease (n=44); 1 patient with measurable disease at baseline and PD as best overall response was excluded due to lack of complete set of target lesion measurements on-study
[b]Patient had an unconfirmed partial response
ESR1=estrogen receptor 1 gene; NE=not evaluable due to missing data for best overall response; PD=progressive disease; PR=confirmed partial response; QD=once daily; SD=stable disease

Figure 6: *A waterfall plot illustrating the best percentage change in target lesion diameter from baseline for each of the 44 (n=44) evaluable patients in the VERITAC expansion cohort. Each bar represents an individual patient, color-coded by dose. Bars below the dashed line at -30% represent a confirmed Partial Response (PR). The analysis reveals a very low rate of meaningful tumor shrinkage, with the majority of patients experiencing either stable disease (SD) or progressive disease (PD) (Hurvitz, S. et al., 2022).*

3. **The Unreliability of Post-Hoc Analysis:** To bolster the narrative, the company highlighted a post-hoc analysis of a small, 8-patient subset that closely matched the planned Phase 3 population, touting a CBR of 62.5%. This is a classic example of statistically invalid "data-dredging." Cherry-picking the best-performing micro-subset of a trial is a common promotional tactic, but such findings are notoriously unreliable and rarely reproducible in a larger, confirmatory trial.

In conclusion, while the VERITAC study successfully de-risked the drug's mechanism and safety, it provided an efficacy signal that was both unreliable by design and underwhelming upon closer inspection. The program was advanced to Phase 3 based on the hope that PFS and other signals would translate into a definitive clinical benefit.

Phase III "VERITAC 2 Study" - NCT05654623

The Phase III VERITAC-2 trial was the definitive, randomized controlled study designed to confirm Vepdegestrant's superiority and secure its position as the new SOC. The trial enrolled 624 (n=624) patients with ER+/HER2- advanced breast cancer who had progressed after one line of CDK4/6 inhibitor-based therapy, randomizing them 1:1 to receive either oral Vepdegestrant or intramuscular fulvestrant. The trial had two co-primary endpoints: Progression-Free Survival (PFS) in the subset of patients with ESR1-mutant tumors, and PFS in the overall population (Arvinas, 2025).

The topline results, presented in March 2025, were a case of a narrow technical "win" that was completely overshadowed by a catastrophic strategic failure, ultimately leading to the collapse of the program's blockbuster potential.

Part A: Progression Free Survival in the ESR1-Mutant Population

The company's public narrative focused exclusively on the positive outcome in the key patient subgroup, presenting it as a major clinical success.

1. **A Statistically Significant Win on a Co-Primary Endpoint:** In the cohort of 270 patients with acquired ESR1 mutations, Vepdegestrant met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in Progression Free Survival. Patients treated with Vepdegestrant had a median PFS of 5.0 months compared to just 2.1 months for those on fulvestrant. This represented a 43% reduction in the risk of progression or death (Hazard Ratio [HR]: 0.57; $p < 0.001$).

Figure 7: *Progression-Free Survival in the ESR1-Mutant Population. Data shown over an 18-month period. In this subgroup, ARV-471 demonstrated significant improvement (Median PFS = 5.0) in treatment over the standard of care, fulvestrant (Median PFS = 2.1). And a Stratified HR of 0.57 p<0.001.*

2. **Supporting Efficacy on Secondary Endpoints:** The win on the primary endpoint was supported by strong positive trends in secondary measures within the ESR1-mutant group. The Objective Response Rate (ORR) was more than four times higher at 18.6% for Vepdegestrant versus just 4.0% for fulvestrant. Similarly, the Clinical Benefit Rate (CBR) was significantly higher at 42.1% versus 20.2%.

3. **A Favorable and Tolerable Safety Profile:** Vepdegestrant was generally well-tolerated, with a safety profile consistent with prior studies. The rates of Grade 3 or higher treatment-related adverse events were low (8% vs. 3% for fulvestrant), and the discontinuation rate due to adverse events was also low (3% vs. 1%).

Based on these results, the company declared the trial a success and announced its intention to file for regulatory approval and NDA submission for the treatment of ESR1-mutant ER+/HER2- breast cancer.

Part B: A Critical Analysis - The Collapse of the Blockbuster Thesis

While technically a success in a single subgroup, a deeper, forensic analysis of the full data set reveals a profound failure that destroyed the "first-line therapeutic" investment thesis.

1. **Failure on the Co-Primary Endpoint in the Overall Population:** The most significant failure was the trial's inability to meet its other primary endpoint. In the overall "all-comers" population of 624 patients, Vepdegestrant failed to demonstrate a statistically significant improvement in PFS. The median PFS was virtually identical between the two arms at 3.7 months for Vepdegestrant versus 3.6 months for fulvestrant (HR: 0.83; p=0.07). This miss instantly invalidated the narrative that Vepdegestrant could be a universal replacement for existing endocrine therapies.

Figure 8: Progression-Free Survival in the Overall, ITT Population. Data shown over an 18-month period. In this subgroup, ARV-471 did not demonstrate significant improvement (Median PFS = 3.7) in treatment over the standard of care, fulvestrant (Median PFS = 3.6). And a Stratified HR of 0.83, p<0.07.

2. **A Modest Benefit Confined to a Niche Subgroup:** Even the "win" in the ESR1-mutant cohort represented a far smaller and less robust opportunity than the headline suggested. The forest plot of Progression-Free Survival across all prespecified subgroups is particularly revealing (Fig. 9). It demonstrates that while the overall Hazard Ratio in the ESR1-mutant population was a favorable 0.57, the treatment effect in many key patient subgroups (such as those with 2 prior lines of therapy or those in North America) was marginal, with confidence intervals crossing 1.0. This visual evidence confirms that the topline "win" was not a reflection of broad, consistent activity, but rather an effect driven heavily by a specific biological context and potentially influenced by geographic or other confounding factors.

Consistent PFS benefit across pre-specified prognostic characteristics/ baseline disease demographics in the ESR1m population

ARVINAS
Pfizer

Subgroup		Events/n Vepdegestrant	Events/n Fulvestrant		HR (95% CI)
All patients (stratified)		79/136	95/134		0.57 (0.42–0.77)
Age, years	<65	50/86	66/88		0.51 (0.35–0.74)
	≥65	29/50	29/46		0.75 (0.45–1.26)
Menopausal status	Pre/perimenopausal	14/28	20/28		0.48 (0.24–0.95)
	Postmenopausal	65/108	75/106		0.60 (0.43–0.85)
Geographic region	Asia	32/56	38/50		0.43 (0.26–0.70)
	Europe	25/41	39/56		0.65 (0.40–1.08)
	North America	13/20	10/16		0.73 (0.32–1.69)
	Other	9/19	8/12		0.71 (0.27–1.89)
ECOG PS	0	46/78	49/76		0.69 (0.46–1.04)
	1	33/58	46/58		0.46 (0.29–0.73)
Visceral disease	Yes	59/92	69/91		0.54 (0.38–0.77)
	No	20/44	26/43		0.65 (0.36–1.18)
Liver disease	Yes	45/63	49/59		0.50 (0.33–0.75)
	No	34/73	46/75		0.60 (0.38–0.94)
Bone-only disease	Yes	8/25	15/24		0.47 (0.20–1.23)
	No	71/111	80/110		0.58 (0.42–0.80)
Lines of prior therapy	1	65/112	76/107		0.54 (0.39–0.75)
	2	14/24	19/27		0.86 (0.43–1.72)

0.1 1 10
HR (95% CI)
◄ Favors vepdegestrant   Favors fulvestrant ►

Figure 9: *A forest plot illustrating the Hazard Ratio (HR) for Progression-Free Survival, comparing Vepdegestrant to fulvestrant across key patient subgroups. Dots to the left of the vertical line at 1.0 favor Vepdegestrant.[4]*

This finding downgrades Vepdegestrant from a potential universal blockbuster to, at best, a niche therapy for the ~40% of patients with this specific mutation. Currently, ~20k patients treated each year, in the U.S., have ESR1 mBC. The ~2.9-month improvement and difference in median PFS, while statistically significant, is unlikely to generate significant enthusiasm among clinicians, who typically look for a 4-6 month benefit to fundamentally change practice, especially with oral chemotherapy as a competing option (Kaklamani et al., 2016).

3. **The Strategic Fallout: Cancellation of the Combination Program:** The failure to establish a broad monotherapy benefit had an immediate and catastrophic domino effect. The entire scientific and commercial rationale for the pivotal Phase 3 VERITAC-3 combination trial, which was predicated on Vepdegestrant being a superior drug, evaporated. The subsequent cancellation of this and other planned combination studies was a clear admission that the broader strategic vision for the drug was no longer viable, instantly erasing a massive portion of its perceived future value.

---

[4] **Analyst note:** While the overall result for the ESR1-mutant population was a statistically significant HR of 0.57, this plot reveals a notable lack of consistent benefit across several important patient categories. For example, the treatment effect was not statistically significant in patients aged ≥65 years, those in North America, or those with two prior lines of therapy, as their confidence intervals cross 1.0. This heterogeneity suggests the topline "win" was not universally robust, further supporting the conclusion that Vepdegestrant's benefit is confined to a niche patient population.

The VERITAC-2 data provided a narrow path to approval in a niche population but served as a definitive and fatal blow to the multi-billion-dollar "best-in-class" and "backbone of choice" thesis that had supported Arvinas's valuation. The results are a powerful case study in the difference between statistical significance in a subgroup and a true, paradigm-shifting clinical success.

Phase III "VERITAC 3" Study - NCT05909397

The failure to establish a broad monotherapy benefit in VERITAC-2 had an immediate and catastrophic effect on Arvinas's broader strategy. The entire scientific and commercial rationale for the pivotal Phase 3 VERITAC-3 trial (NCT05909397), which was predicated on Vepdegestrant being a superior backbone compared to fulvestrant, for combination therapy with palbociclib, evaporated overnight.

The subsequent cancellation of this and other planned combination studies was a clear admission from the company that the thesis was no longer viable. This strategic decision erased a massive portion of the drug's perceived future value and marked the definitive end of its blockbuster potential, confirming that the VERITAC-2 failure was not just a clinical setback, but a franchise-ending event.

Discussion: Synthesizing the Reasons for Failure

The definitive failure of Vepdegestrant in the pivotal VERITAC-2 trial was not an unpredictable event, but rather the logical culmination of fundamental risks that were identifiable from the earliest stages of its development. The disconnect between the profound preclinical promise and the disappointing clinical reality can be explained by two core failures: a flawed clinical development strategy built upon unreliable data, and a fundamental pharmacological failure rooted in the molecule's challenging chemistry. This was not a failure of a well-validated biological target, but a failure of both strategy and execution.

Hypothesis 1: A Flawed Clinical Strategy Built on Unreliable Data: The decision to launch a massive and costly Phase 3 program was a critical strategic error based on a profound over-interpretation of weak and fundamentally unreliable Phase II data. The case that supported the company's multi-billion dollar valuation was built on the results of the VERITAC expansion cohort. An analysis of this trial reveals the study was flawed in both its design and its data.

The primary design flaw was its nature as a single-arm, open-label trial. Lacking a randomized, concurrent control arm, it is impossible to definitively attribute the observed 3.7-month median Progression-Free Survival to the drug's activity versus confounding factors like patient selection

bias. Designing a trial without a validated control arm, elacestrant or fulvestrant in this case, is unreliable in gauging a drug's true efficacy.

Even within this flawed design, the efficacy signal itself was far weaker than the headline numbers suggested. The company promoted a 38% Clinical Benefit Rate (CBR), a soft endpoint that includes patients with stable disease. A deeper analysis of the data reveals a true Objective Response Rate of just 4.5% in patients with measurable disease, indicating a profound lack of meaningful tumor regression. Furthermore, the company's narrative was bolstered by a post-hoc analysis of a small, 8-patient subset that touted a 62.5% CBR. The failure of VERITAC-2 was therefore predictable; the decision to advance the program was based on ambiguous signals from a study that was both unreliable by design and underwhelming upon closer inspection.

Hypothesis 2: A Fundamental Pharmacological Failure of the Molecule: Independent of the strategic decisions, Vepdegestrant failed because its clinical pharmacokinetics were insufficient to deliver the pharmacodynamic effect required for a robust anti-tumor response. This is the clinical example of an"active but not effective" medication, a failure rooted in the molecule's foundational chemistry.

The root cause was Vepdegestrant's poor "druggability" properties, particularly its high molecular weight and lipophilicity (Table 1), which predisposed it to a poor pharmacokinetic profile. This theoretical risk was confirmed in the first-in-human clinical studies, which established a clinical half-life of just 20.2 hours.

This short half-life created a critical disconnect between the drug's biological activity and its clinical effect. The ~20-hour half-life was sufficient to demonstrate "biological activity" by engaging the target and producing a temporary biomarker effect (a reduction in ESR1 VAF). However, this duration of exposure was insufficient to sustain the deep, multi-day ER degradation (≥90%) that preclinical models had shown was necessary to induce tumor regression. The median human ER degradation of 69% in the VERITAC study already hinted at this translational gap.

The final, definitive outcome of this pharmacological failure was the non-significant benefit observed in the VERITAC-2 trial. The nearly identical median PFS in the overall population (vepdegestrant = 3.7 vs. fulvestrant = 3.6 months) is the clinical signature of a drug that can bind its target, but cannot sustain that binding at a high enough concentration or for a long enough duration to produce a statistically significant clinical benefit. Ultimately, the elegant preclinical theory could not overcome the reality of a flawed molecule's performance in human patients.

Valuation Analysis: Quantifying the Failure

The valuation of Arvinas (NASDAQ: ARVN) has been fundamentally reset following the pivotal VERITAC-2 trial. Previously, the company's multi-billion dollar valuation was underpinned by the blockbuster potential of Vepdegestrant as a new SOC treatment in ER+/HER2- breast cancer. With the failure of the trial in the broad population, the investment case now rests on the niche commercial opportunity for Vepdegestrant in the ESR1-mutant setting, and the future potential of the company's early-stage pipeline.

To quantify the financial impact of this new reality, it is prudent to establish a credible floor valuation for Arvinas based on the tangible assets that remain.

Valuation Methodology: A Fundamental Approach: For this postmortem analysis, I perform a fundamental Unlevered Discounted Cash Flow (DCF) Analysis. This model, detailed in the Appendix, projects the company's future cash flows based on a conservative scenario and discounts them to the present day. This DCF-driven approach is the most appropriate method for this post-failure context, as it provides a credible, intrinsic valuation for the company based solely on its ability to generate cash from its de-risked assets, without relying on speculative market sentiment.

Floor Valuation: A Niche Drug and an Early Pipeline (~$8.00/share)
Key Assumptions:
- **Vepdegestrant Revenue:** My model forecasts a conservative, niche launch for Vepdegestrant in the 2nd/3rd line, ER+/HER2-, ESR1-mutant population. My key inputs are:
  - **Peak Market Share:** I assume a conservative peak market share of 30% of this niche population.
  - **Pricing:** I model a wholesale acquisition cost (WAC) of $12,000 per month.
  - **Treatment Duration:** I model an average of 6 months on therapy, in line with the mPFS for the ESR1-mutant breast cancer subgroup.
  - **Gross-to-Net:** I apply a 25% gross-to-net adjustment.
  - **Co-Commercialization:** I apply the 50/50 profit/cost share with Pfizer.
  - **Peak Revenue:** These assumptions result in peak, risk-adjusted revenue to Arvinas of ~$227M.
- **Pipeline Value:** I conservatively ascribe zero explicit revenue value to the rest of Arvinas's early-stage pipeline. The costs to fund this pipeline, however, are included in my expense forecast.
- **Operating Expenses:**
  - COGS: Modeled at a stable 18% of net product sales.
  - R&D: Modeled at a long-term rate of 30% of total revenue.
  - SG&A: Modeled to support the launch, peaking at 40% of product sales and declining to a stable 25% long-term.

The Floor Valuation is derived directly from a 10-year Unlevered DCF model, detailed in Appendix A. This analysis provides what I believe is the most credible intrinsic value for Arvinas in a reasonable scenario.

- The DCF model, which projects unlevered free cash flows through 2035 and discounts them back to today at a 12.5% discount rate (reflecting the heightened risk), yields a total Enterprise Value of $115M.
- To determine the value attributable to shareholders, we adjust this Enterprise Value for the company's net cash position. Adding Net Cash of $456M results in an Implied Equity Value of $571M.
- Dividing this Implied Equity Value by the 73 million diluted shares outstanding results in a fundamental Floor Valuation of ~$7.80 per share.[5]

---

[5] **Analyst Note on Valuation Risks and Limitations:** It is critical to note that my valuation of ~$7.80 per share is predicated on the successful submission and subsequent FDA approval of the Vepdegestrant New Drug Application (NDA) for the ESR1-mutant indication. This model does not explicitly risk-adjust for several significant downstream hurdles. These include challenges in commercial execution against future competitors, market adoption rates, and potential payer pressure on pricing given the drug's incremental clinical benefit. Additionally, this model assigns no value to the PROTAC pipeline currently owned and operated by Arvinas Inc. due to the significant risks associated. Furthermore, this DCF represents a "success-case" scenario and does not apply a formal conjunctive probability framework to discount for these multiple, independent risks. Therefore, this valuation should be viewed as an intrinsic value assuming a successful and well-executed launch, and it remains subject to considerable commercial and regulatory risk.

Conclusion & Forward Looking Implications

The pivotal failure of Vepdegestrant is a powerful and definitive case study in the immense challenge of translating a promising scientific theory into a successful therapeutic. My deep-dive analysis reveals a clear and logical narrative: an elegant biological hypothesis, embodied by a fundamentally flawed molecule, was advanced based on ambiguous early-stage data, leading to a predictable and franchise-ending failure in a rigorous, randomized clinical trial.

A Molecule-Specific Failure, and a Cautionary Tale for the PROTAC Field: My analysis strongly supports the conclusion that this was primarily a molecule-specific failure rooted in poor medicinal chemistry. Early clinical data prove that the PROTAC mechanism itself was working as intended. However, the drug's challenging physicochemical properties were simply insufficient to deliver the sustained target degradation required. While not an indictment of the platform, this failure serves as a cautionary tale for the field of orally targeted protein degradation. It significantly raises the bar for future candidates, demonstrating that a powerful mechanism of action cannot overcome fundamental deficits in "druggability." The success of future oral PROTACs will be dictated not just by their biological potency, but by their ability to demonstrate excellent, durable pharmacokinetic profiles in human patients.

Implications for Arvinas (ARVN): My fundamental DCF analysis suggests a floor valuation for Arvinas of ~$7.80 per share. This indicates that at its current market price, the company is now being accurately valued for its post-failure reality: a business supported by its substantial net cash balance and the modest, tangible value of Vepdegestrant's niche opportunity in the ESR1-mutant population. The "blockbuster" premium has been completely erased.

The investment case for Arvinas no longer rests solely on Vepdegestrant. It now hinges on the scientific and commercial viability of its remaining pipeline, particularly its androgen receptor (AR) degrader, bavdegalutamide (ARV-110), for prostate cancer. Investors will be intensely focused on its pharmacokinetic profile and any signs that it can avoid the same pitfalls that led to Vepdegestrant's commercial failure.

Final Takeaways: Frameworks for Analyzing Novel Therapeutics
1. Medicinal Chemistry is Paramount: For novel therapeutics like PROTACs, scrutinizing the fundamental physicochemical properties (e.g., molecular weight, LogP) is as important, if not more important, than the preclinical biological data. An elegant mechanism does not make up for a flawed molecule.
2. Beware the "Active but Not Effective" Paradox: A positive biomarker signal is not a substitute for a positive clinical outcome. The most critical question is whether a drug's pharmacokinetic profile can sustain its pharmacodynamic effect at a high enough concentration, and for a long enough duration, to be clinically significant.
3. Clinical Trial Structure: Promising efficacy signals from small, single-arm, open-label studies should be viewed with extreme skepticism until they are validated in a large, randomized, and well-controlled pivotal trial.

Appendix

Appendix A: Unlevered DCF Model (Floor Valuation)

Note: All figures are in millions USD, unless otherwise noted.

Fiscal Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036
Total Revenue	75	95	130	160	190	210	220	227	215	200	180
Gross Profit	71	83	108	131	156	172	180	186	176	164	148
R&D Expense	(23)	(29)	(39)	(48)	(57)	(63)	(66)	(68)	(65)	(60)	(54)
SG&A Expense	(20)	(40)	(60)	(70)	(76)	(74)	(66)	(57)	(54)	(50)	(45)
Operating Income (EBIT)	23	1	(13)	(16)	(11)	(2)	8	20	19	18	17
Taxes (at 21%)	(5)	(0)	3	3	2	0	(2)	(4)	(4)	(4)	(4)
NOPAT	18	1	(10)	(13)	(9)	(2)	6	16	15	14	13

Appendix B: DCF Valuation Summary

Metric	Value
Present Value of FCF (NPV)[6]	$115 M
Discount Rate (WACC)	12.5%
Implied Enterprise Value	$115 M
Plus: Net Cash[7]	$456M
Implied Equity Value	$571 M
Shares Outstanding (Diluted)[8]	73 M
Implied Equity Value per Share	~$7.80

[6,7,8] **Analyst Note: Present Value of FCF (NPV)[5]:** The Net Present Value is the sum of all future unlevered free cash flows (UFCF), discounted back to the present day. For this model, I have assumed that UFCF is equal to NOPAT (Net Operating Profit After Tax), a common simplification for biotech companies where Depreciation & Amortization is assumed to be fully offset by maintenance Capital Expenditures, and the Change in Net Working Capital is negligible. A terminal growth rate of -5% is applied after the explicit forecast period. **Net Cash[6]:** Calculated from the company's most recent balance sheet (e.g., Q2 2025). Net Cash = (Cash & Cash Equivalents + Marketable Securities) - (Total Debt). **Shares Outstanding (Diluted)[7]:** Based on the most recently reported weighted-average diluted share count, grown at a conservative 2% annually to account for future dilution from stock-based compensation.

Disclaimers

Analyst Certification
I, Justin Marciano, hereby certify that all of the views expressed in this research report accurately reflect my personal views about the subject, security, and company. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

General Disclaimer: This document is for informational and educational purposes only and should not be construed as a recommendation or offer to buy or sell any security. The information contained herein is based on sources I believe to be reliable, but I do not guarantee its accuracy or completeness. All estimates, opinions, and valuations expressed in this report constitute my judgment as of the date of this report and are subject to change without notice. Investing in securities involves significant risks, including the risk of losing the entire principal amount. Readers should conduct their own research and consult with a professional financial advisor before making any investment decisions.

Company-Specific Disclosures:

- As of the date of this report September 19, 2025, I do not hold a financial interest or any shares in Arvinas Inc. (NASDAQ: ARVN).
- I do not have any Investment Banking or other business relationships with Arvinas, Inc.

Editor's Note: This article is part of a biotech valuation series I'm publishing to demonstrate my industry knowledge and investment approach. If you're a hiring manager or recruiter, feel free to reach out. I'm looking for roles in [Equity Research / Corporate Strategy / Biotech & Biopharma Investing / Investment Banking].

References

Arvinas, Inc. "ARV-471: Phase 2 VERITAC Trial Results." San Antonio Breast Cancer
    Symposium, 8 Dec. 2022. Corporate Presentation.

Arvinas, Inc. "PHASE 3 VERITAC-2 TRIAL RESULTS." 2 June 2025. Corporate Presentation.

Chamberlain, Philip P., and Lennon G. Hamann. "Development of Targeted Protein Degradation
    Therapeutics." Nature Chemical Biology, vol. 15, no. 10, Oct. 2019, pp. 937-44,
    https://doi.org/10.1038/s41589-019-0362-y.

Crews, Craig M. "Craig M. Crews, PhD." Yale School of Medicine,
    medicine.yale.edu/profile/craig-crews/. Accessed 19 Sept. 2025.

Fribbens, Charlotte, et al. "Plasma ESR1 Mutations and the Treatment of Estrogen
    Receptor–Positive Advanced Breast Cancer." Journal of Clinical Oncology, vol. 34, no.
    25, Sept. 2016, pp. 2961-68, https://doi.org/10.1200/JCO.2016.67.3061.

Gough, Sheryl M., et al. "Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly
    Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway
    Inhibitors in Preclinical ER+ Breast Cancer Models." Clinical Cancer Research, vol. 30,
    no. 16, Aug. 2024, pp. 3549-63, https://doi.org/10.1158/1078-0432.CCR-23-3465.

Hamilton, Erika P., et al. "VERITAC-2: A Phase III Study of Vepdegestrant, a PROTAC ER
    Degrader, Versus Fulvestrant in ER+/HER2- Advanced Breast Cancer." Future
    Oncology, vol. 20, no. 32, Oct. 2024, pp. 2447-55,
    https://doi.org/10.1080/14796694.2024.2377530.

Harbeck, Nadia, and Michael Gnant. "Breast Cancer." The Lancet, vol. 389, no. 10074, Mar.
    2017, pp. 1134-50.

Iwata, Hiroji, et al. "Safety and Pharmacokinetics of Vepdegestrant in Japanese Patients with
    ER+ Advanced Breast Cancer: A Phase 1 Study." International Journal of Clinical
    Oncology, vol. 30, no. 1, Jan. 2025, pp. 72-82,
    https://doi.org/10.1007/s10147-024-02648-3.

Jeselsohn, Rinath, et al. "ESR1 Mutations—A Mechanism for Acquired Endocrine Resistance in
    Breast Cancer." Nature Reviews Clinical Oncology, vol. 12, no. 10, Oct. 2015, pp. 573-83,
    https://doi.org/10.1038/nrclinonc.2015.117.

Kaklamani, Virginia G. "Clinical Implications of the Progression-Free Survival Endpoint for
    Treatment of Hormone Receptor-Positive Advanced Breast Cancer." The Oncologist, vol.
    21, no. 8, Aug. 2016, pp. 922-30, https://doi.org/10.1634/theoncologist.2015-0366.
    National Center for Biotechnology Information.

Peck, Ronald, et al. "PROTAC Compounds and Uses Thereof." Patent WO 2024/049922 A1, World Intellectual Property Organization, 14 Mar. 2024. Google Patents, patents.google.com/patent/WO2024049922A1/en.

"PubChem Compound Summary for CID 134562533, Arv-471." PubChem, pubchem.ncbi.nlm.nih.gov/compound/Arv-471. Accessed 19 Sept. 2025.

"PubChem Compound Summary for CID 23642301, Elacestrant." PubChem, pubchem.ncbi.nlm.nih.gov/compound/Elacestrant. Accessed 19 Sept. 2025.

Raina, Kanak, et al. "PROTAC-induced BET Protein Degradation as a Therapy for Castration-Resistant Prostate Cancer." Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 26, June 2016, pp. 7124-29, https://doi.org/10.1073/pnas.1521738113.

Snyder, Lawrence B. "The Discovery of ARV-471, an Orally Bioavailable Estrogen Receptor Degrading PROTAC® for the Treatment of Patients with Breast Cancer." TIDES USA: Oligonucleotide and Peptide Therapeutics Conference, 15-18 May 2021, Boston, MA. Conference Presentation.

The Cancer Genome Atlas Network. "Comprehensive Molecular Portraits of Human Breast Tumours." Nature, vol. 490, no. 7418, Oct. 2012, pp. 61-70.